产品封面图

pmCherry-N1

收藏
  • ¥800 - 1200
  • Ybscience
  • 中国/美国
  • YB-0571
  • 2025年07月08日
    avatar
  • 企业认证

    点击 QQ 联系

  • 万千商家帮你免费找货

    0 人在求购买到急需产品
    • 详细信息
    • 文献和实验
    • 技术资料
    • 保存条件

      -20℃

    • 保质期

      6个月

    • 英文名

      pmCherry-N1

    • 库存

      大量

    • 供应商

      钰博生物

    • 规格

      1ug/5ug

    pmCherry-N1

    载体基本信息

    出品公司: Ybscience
    载体名称: pmCherry-N1
    质粒类型: 哺乳细胞表达载体;荧光蛋白报告系统
    高拷贝/低拷贝: --
    启动子: CMV
    克隆方法: 多克隆位点,限制性内切酶
    载体大小: 4722bp
    5' 测序引物及序列: CMV-F: CGCAAATGGGCGGTAGGCGTG
    3' 测序引物及序列: mCherry-R: TTGGTCACCTTCAGCTTGG
    载体标签: mCherry
    载体抗性: Kanamycin
    筛选标记: Neomycin
    备注: --\
    稳定性: --
    组成型: --
    病毒/非病毒: 非病毒
     

    载体质粒图谱和多克隆位点信息

    pmCherry-N1载体图谱



    pmCherry-N1多克隆位点

    pmCherry-N1载体特征
    pmCherry-N1载体特征2

    载体简介

     

    载体序列

    LOCUS       pmCherry-N1	4722 bp 	DNA	SYN
    DEFINITION  pmCherry-N1
    ACCESSION   
    KEYWORDS    
    SOURCE      
      ORGANISM  other sequences; artificial sequences; vectors.
    FEATURES             Location/Qualifiers
         source          1..4722
                         /organism="pmCherry-N1"
                         /mol_type="other DNA"
         promoter        10..562
                         /label="CMV_immearly_promoter"
         misc_feature    65..352
                         /label="CAG_enhancer"
         misc_feature    519..539
                         /label="CMV_fwd_primer"
         promoter        520..589
                         /label="CMV_promoter"
         CDS             complement(607..1419)
                         /label="ORF frame 1"
                        
         CDS             679..1389
                         /label="ORF frame 1"
                         
         gene            682..1386
                         /label="mCherry"
                         /gene="mCherry"
                         
         misc_feature    859..912
                         /label="Q66M (mCherry)"
                     
         misc_feature    1601..1620
                         /label="EBV_rev_primer"
                       
         rep_origin      complement(1770..2076)
                         /label="f1_origin"
                        
         promoter        2155..2183
                         /label="AmpR_promoter"
                       
         misc_feature    complement(2249..2269)
                         /label="pBABE_3_primer"
                      
         misc_feature    complement(2255..2470)
                         /label="SV40_enhancer"
                       
         promoter        2267..2535
                         /label="SV40_promoter"
                       
         rep_origin      2434..2511
                         /label="SV40_origin"
                        
         misc_feature    2496..2515
                         /label="SV40pro_F_primer"
                       
         CDS             2618..3412
                         /label="ORF frame 2"
                       
         gene            2621..3409
                         /label="NeoR/KanR"
                         /gene="NeoR/KanR"
                      
         CDS             complement(2927..3463)
                         /label="ORF frame 3"
                       
         terminator      3587..3856
                         /label="TK_PA_terminator"
                       
         rep_origin      4004..4623
                         /label="pBR322_origin"
                        
    ORIGIN
        1 TAGTTATTAA TAGTAATCAA TTACGGGGTC ATTAGTTCAT AGCCCATATA TGGAGTTCCG
       61 CGTTACATAA CTTACGGTAA ATGGCCCGCC TGGCTGACCG CCCAACGACC CCCGCCCATT
      121 GACGTCAATA ATGACGTATG TTCCCATAGT AACGCCAATA GGGACTTTCC ATTGACGTCA
      181 ATGGGTGGAG TATTTACGGT AAACTGCCCA CTTGGCAGTA CATCAAGTGT ATCATATGCC
      241 AAGTACGCCC CCTATTGACG TCAATGACGG TAAATGGCCC GCCTGGCATT ATGCCCAGTA
      301 CATGACCTTA TGGGACTTTC CTACTTGGCA GTACATCTAC GTATTAGTCA TCGCTATTAC
      361 CATGGTGATG CGGTTTTGGC AGTACATCAA TGGGCGTGGA TAGCGGTTTG ACTCACGGGG
      421 ATTTCCAAGT CTCCACCCCA TTGACGTCAA TGGGAGTTTG TTTTGGCACC AAAATCAACG
      481 GGACTTTCCA AAATGTCGTA ACAACTCCGC CCCATTGACG CAAATGGGCG GTAGGCGTGT
      541 ACGGTGGGAG GTCTATATAA GCAGAGCTGG TTTAGTGAAC CGTCAGATCC GCTAGCGCTA
      601 CCGGACTCAG ATCTCGAGCT CAAGCTTCGA ATTCTGCAGT CGACGGTACC GCGGGCCCGG
      661 GATCCACCGG TCGCCACCAT GGTGAGCAAG GGCGAGGAGG ATAACATGGC CATCATCAAG
      721 GAGTTCATGC GCTTCAAGGT GCACATGGAG GGCTCCGTGA ACGGCCACGA GTTCGAGATC
      781 GAGGGCGAGG GCGAGGGCCG CCCCTACGAG GGCACCCAGA CCGCCAAGCT GAAGGTGACC
      841 AAGGGTGGCC CCCTGCCCTT CGCCTGGGAC ATCCTGTCCC CTCAGTTCAT GTACGGCTCC
      901 AAGGCCTACG TGAAGCACCC CGCCGACATC CCCGACTACT TGAAGCTGTC CTTCCCCGAG
      961 GGCTTCAAGT GGGAGCGCGT GATGAACTTC GAGGACGGCG GCGTGGTGAC CGTGACCCAG
     1021 GACTCCTCCC TGCAGGACGG CGAGTTCATC TACAAGGTGA AGCTGCGCGG CACCAACTTC
     1081 CCCTCCGACG GCCCCGTAAT GCAGAAGAAG ACCATGGGCT GGGAGGCCTC CTCCGAGCGG
     1141 ATGTACCCCG AGGACGGCGC CCTGAAGGGC GAGATCAAGC AGAGGCTGAA GCTGAAGGAC
     1201 GGCGGCCACT ACGACGCTGA GGTCAAGACC ACCTACAAGG CCAAGAAGCC CGTGCAGCTG
     1261 CCCGGCGCCT ACAACGTCAA CATCAAGTTG GACATCACCT CCCACAACGA GGACTACACC
     1321 ATCGTGGAAC AGTACGAACG CGCCGAGGGC CGCCACTCCA CCGGCGGCAT GGACGAGCTG
     1381 TACAAGTAGC GGCCGCGACT CTAGATCATA ATCAGCCATA CCACATTTGT AGAGGTTTTA
     1441 CTTGCTTTAA AAAACCTCCC ACACCTCCCC CTGAACCTGA AACATAAAAT GAATGCAATT
     1501 GTTGTTGTTA ACTTGTTTAT TGCAGCTTAT AATGGTTACA AATAAAGCAA TAGCATCACA
     1561 AATTTCACAA ATAAAGCATT TTTTTCACTG CATTCTAGTT GTGGTTTGTC CAAACTCATC
     1621 AATGTATCTT AAGGCGTAAA TTGTAAGCGT TAATATTTTG TTAAAATTCG CGTTAAATTT
     1681 TTGTTAAATC AGCTCATTTT TTAACCAATA GGCCGAAATC GGCAAAATCC CTTATAAATC
     1741 AAAAGAATAG ACCGAGATAG GGTTGAGTGT TGTTCCAGTT TGGAACAAGA GTCCACTATT
     1801 AAAGAACGTG GACTCCAACG TCAAAGGGCG AAAAACCGTC TATCAGGGCG ATGGCCCACT
     1861 ACGTGAACCA TCACCCTAAT CAAGTTTTTT GGGGTCGAGG TGCCGTAAAG CACTAAATCG
     1921 GAACCCTAAA GGGAGCCCCC GATTTAGAGC TTGACGGGGA AAGCCGGCGA ACGTGGCGAG
     1981 AAAGGAAGGG AAGAAAGCGA AAGGAGCGGG CGCTAGGGCG CTGGCAAGTG TAGCGGTCAC
     2041 GCTGCGCGTA ACCACCACAC CCGCCGCGCT TAATGCGCCG CTACAGGGCG CGTCAGGTGG
     2101 CACTTTTCGG GGAAATGTGC GCGGAACCCC TATTTGTTTA TTTTTCTAAA TACATTCAAA
     2161 TATGTATCCG CTCATGAGAC AATAACCCTG ATAAATGCTT CAATAATATT GAAAAAGGAA
     2221 GAGTCCTGAG GCGGAAAGAA CCAGCTGTGG AATGTGTGTC AGTTAGGGTG TGGAAAGTCC
     2281 CCAGGCTCCC CAGCAGGCAG AAGTATGCAA AGCATGCATC TCAATTAGTC AGCAACCAGG
     2341 TGTGGAAAGT CCCCAGGCTC CCCAGCAGGC AGAAGTATGC AAAGCATGCA TCTCAATTAG
     2401 TCAGCAACCA TAGTCCCGCC CCTAACTCCG CCCATCCCGC CCCTAACTCC GCCCAGTTCC
     2461 GCCCATTCTC CGCCCCATGG CTGACTAATT TTTTTTATTT ATGCAGAGGC CGAGGCCGCC
     2521 TCGGCCTCTG AGCTATTCCA GAAGTAGTGA GGAGGCTTTT TTGGAGGCCT AGGCTTTTGC
     2581 AAAGATCGAT CAAGAGACAG GATGAGGATC GTTTCGCATG ATTGAACAAG ATGGATTGCA
     2641 CGCAGGTTCT CCGGCCGCTT GGGTGGAGAG GCTATTCGGC TATGACTGGG CACAACAGAC
     2701 AATCGGCTGC TCTGATGCCG CCGTGTTCCG GCTGTCAGCG CAGGGGCGCC CGGTTCTTTT
     2761 TGTCAAGACC GACCTGTCCG GTGCCCTGAA TGAACTGCAA GACGAGGCAG CGCGGCTATC
     2821 GTGGCTGGCC ACGACGGGCG TTCCTTGCGC AGCTGTGCTC GACGTTGTCA CTGAAGCGGG
     2881 AAGGGACTGG CTGCTATTGG GCGAAGTGCC GGGGCAGGAT CTCCTGTCAT CTCACCTTGC
     2941 TCCTGCCGAG AAAGTATCCA TCATGGCTGA TGCAATGCGG CGGCTGCATA CGCTTGATCC
     3001 GGCTACCTGC CCATTCGACC ACCAAGCGAA ACATCGCATC GAGCGAGCAC GTACTCGGAT
     3061 GGAAGCCGGT CTTGTCGATC AGGATGATCT GGACGAAGAG CATCAGGGGC TCGCGCCAGC
     3121 CGAACTGTTC GCCAGGCTCA AGGCGAGCAT GCCCGACGGC GAGGATCTCG TCGTGACCCA
     3181 TGGCGATGCC TGCTTGCCGA ATATCATGGT GGAAAATGGC CGCTTTTCTG GATTCATCGA
     3241 CTGTGGCCGG CTGGGTGTGG CGGACCGCTA TCAGGACATA GCGTTGGCTA CCCGTGATAT
     3301 TGCTGAAGAG CTTGGCGGCG AATGGGCTGA CCGCTTCCTC GTGCTTTACG GTATCGCCGC
     3361 TCCCGATTCG CAGCGCATCG CCTTCTATCG CCTTCTTGAC GAGTTCTTCT GAGCGGGACT
     3421 CTGGGGTTCG AAATGACCGA CCAAGCGACG CCCAACCTGC CATCACGAGA TTTCGATTCC
     3481 ACCGCCGCCT TCTATGAAAG GTTGGGCTTC GGAATCGTTT TCCGGGACGC CGGCTGGATG
     3541 ATCCTCCAGC GCGGGGATCT CATGCTGGAG TTCTTCGCCC ACCCTAGGGG GAGGCTAACT
     3601 GAAACACGGA AGGAGACAAT ACCGGAAGGA ACCCGCGCTA TGACGGCAAT AAAAAGACAG
     3661 AATAAAACGC ACGGTGTTGG GTCGTTTGTT CATAAACGCG GGGTTCGGTC CCAGGGCTGG
     3721 CACTCTGTCG ATACCCCACC GAGACCCCAT TGGGGCCAAT ACGCCCGCGT TTCTTCCTTT
     3781 TCCCCACCCC ACCCCCCAAG TTCGGGTGAA GGCCCAGGGC TCGCAGCCAA CGTCGGGGCG
     3841 GCAGGCCCTG CCATAGCCTC AGGTTACTCA TATATACTTT AGATTGATTT AAAACTTCAT
     3901 TTTTAATTTA AAAGGATCTA GGTGAAGATC CTTTTTGATA ATCTCATGAC CAAAATCCCT
     3961 TAACGTGAGT TTTCGTTCCA CTGAGCGTCA GACCCCGTAG AAAAGATCAA AGGATCTTCT
     4021 TGAGATCCTT TTTTTCTGCG CGTAATCTGC TGCTTGCAAA CAAAAAAACC ACCGCTACCA
     4081 GCGGTGGTTT GTTTGCCGGA TCAAGAGCTA CCAACTCTTT TTCCGAAGGT AACTGGCTTC
     4141 AGCAGAGCGC AGATACCAAA TACTGTCCTT CTAGTGTAGC CGTAGTTAGG CCACCACTTC
     4201 AAGAACTCTG TAGCACCGCC TACATACCTC GCTCTGCTAA TCCTGTTACC AGTGGCTGCT
     4261 GCCAGTGGCG ATAAGTCGTG TCTTACCGGG TTGGACTCAA GACGATAGTT ACCGGATAAG
     4321 GCGCAGCGGT CGGGCTGAAC GGGGGGTTCG TGCACACAGC CCAGCTTGGA GCGAACGACC
     4381 TACACCGAAC TGAGATACCT ACAGCGTGAG CTATGAGAAA GCGCCACGCT TCCCGAAGGG
     4441 AGAAAGGCGG ACAGGTATCC GGTAAGCGGC AGGGTCGGAA CAGGAGAGCG CACGAGGGAG
     4501 CTTCCAGGGG GAAACGCCTG GTATCTTTAT AGTCCTGTCG GGTTTCGCCA CCTCTGACTT
     4561 GAGCGTCGAT TTTTGTGATG CTCGTCAGGG GGGCGGAGCC TATGGAAAAA CGCCAGCAAC
     4621 GCGGCCTTTT TACGGTTCCT GGCCTTTTGC TGGCCTTTTG CTCACATGTT CTTTCCTGCG
     4681 TTATCCCCTG ATTCTGTGGA TAACCGTATT ACCGCCATGC AT

    风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。

    图标文献和实验
    相关实验
    • 【求助】请问PC12 N1代表什么?

      sadows 看一篇文献摘要里多次提到PC12 N1,N1代表什么,是PC12细胞中的一型么?那一型呢?PC12不是只有分化的和没分化的么?望达人赐教.谢谢摘要如下: JNKs, also known as SAPKs, are activated in response to a wide variety of factors including growth factors, cytokines, UV radiation, and heat

    • pEGFP-N1质粒图谱及信息

      多克隆位点区 Restriction Map and Multiple Cloning Site of pEGFP-N1. (Unique restriction sites are in color or bold.) The Not I site follows the EGFP stop codon. The Xba I site (*) is methylated in the DNA provided by CLONTECH. If you wish to digest

    • Spermidine/Spermine-N1-Acetyltransferase in Kidney Ischemia Reperfusion Injury

      reperfusion injury and can be therapeutically targeted will lead to development of new approaches for the treatment of such injuries. The expression of spermidine/spermine-N1 -acetyltransferase increases in the kidneys subjected to ischemic reperfusion injury

    图标技术资料

    暂无技术资料 索取技术资料

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    ¥1080
    武汉维克赛思科技有限公司
    2025年08月05日询价
    ¥1
    上海联迈生物工程有限公司
    2026年01月07日询价
    ¥1200
    上海晶风生物科技有限公司
    2025年03月26日询价
    ¥1000
    上海盖宁生物科技有限公司
    2026年03月11日询价
    ¥680
    温州科淼生物科技有限公司
    2025年07月16日询价
    pmCherry-N1
    ¥800 - 1200